Environment

Increasing scientific evidence demonstrates that climate change and nature loss are impacting the world and human health in many ways, including extreme heat contributing to deaths from diseases, increased spread of infectious diseases and air pollution exacerbating respiratory diseases.

The Lancet Commission on Health and Climate Change stated that “addressing climate change is the greatest public health opportunity for the century”.

As a science-based healthcare company, addressing our environmental impact is fundamental to our purpose, so that together with our partners, we can help protect and restore the planet’s health, in order to protect and improve people’s health.

In November 2020, we announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a:

We have long been committed to reducing our environmental impact and we were one of the first pharmaceutical companies to set ambitious environment targets in 2010. Since then, across our operations, we have reduced carbon emissions by 34%, waste to landfill by 78% and total water use by 31% (2019 figures).

Delivering our new environmental sustainability goals

The new goals represent a significant new level of ambition and form part of our Trust priority and ESG approach, which support our aim to create long-term value for shareholders and meet the needs of society.  

Over the next decade, we will invest in measures to reduce our environmental impact and in restoration projects to balance the remaining impact that we cannot reduce and aim to put back into nature more than we take out.

In order to achieve these goals, we have set a number of specific targets across our direct operations, supply chains and portfolio. We intend to achieve most of these targets by 2030, but where we can accelerate timelines we have committed to an earlier date.

Meeting these new goals will require working across our value chain – from discovery to disposal - and we will work closely with our suppliers, customers, consumers, patients, and external experts, and we are grateful for their support.

Our new environmental sustainability targets

The new goals apply principally to GSK’s Biopharma business and portfolio. Our Consumer Healthcare business will also contribute towards these goals through delivery of its own targets, whilst it is part of GSK.

We will report progress against these underlying targets and two goals on an annual basis, disclosed as part of our Annual Report and ESG reporting from 2021. In our latest 2020 report, we reported against our 2018 targets for a final time.

Delivering on our targets – climate and nature action working together

We will deliver our new environmental targets by taking action on priority impact areas and working with key external partners including suppliers and customers. Our climate and nature goals are interconnected and mutually reinforcing, and we will seek to strengthen those links and benefits wherever possible.

To achieve our net zero goal on climate we will reduce emissions as far as possible, as well as investing in nature-based carbon removal projects linked to biodiversity improvements, which serve to remove carbon and are also nature positive. Examples include tree planting to restore previously forested areas and restoration of mangroves in coastal areas, that store carbon and boost healthy ecosystems.

Progress on many of our nature targets will also reduce our carbon emissions, for example reducing the amount of product packaging will also reduce carbon emissions in manufacturing, logistics and transport. For more on our nature progress, see water, waste and environmental stewardship.

Net zero impact on climate

The Science Based Targets Initiative has accredited that our new carbon targets align to a 1.5° pathway – in line with the most ambitious goal of the Paris Agreement. We have also joined RE100 and EV100 making a commitment to use 100% renewable electricity and transition 100% of our sales fleet to low emission vehicles.

Our climate strategy covers the full value chain of emissions reductions across our own operations, our supplier base and emissions from patient use of our products. This is in line with the Science Based Target Initiative carbon reduction pathway. Across our Biopharma and Consumer Healthcare businesses, the proportion of carbon we anticipate off-setting is less than 20% overall of total emissions. Read more about our climate approach here.

The Environmental Sustainability Supplier awards

We recognise the key role our suppliers play in helping us achieve our sustainability goals. Every year we run the Environmental Sustainability Supplier awards to recognise our suppliers’ contribution to environmental sustainability. The 2021 winners were Zuellig Pharma, Sai Life Sciences and Givaudan. For more detail, see the case studies below:

• Zuellig PharmaPDF - 228.2KB
• Sai Life SciencesPDF - 273.8KB
• GivaudanPDF - 201.4KB

Net positive impact on nature

Measuring and accounting for how companies impact the natural world is an emerging field. We are collaborating with partners to understand how best to measure our nature impacts and meet industry standards, for example working with the World Business Council of Sustainable Development and the UN Environment Programme to contribute to the Science Based Targets Network for nature.

We will align to the Science Based Targets Network approach to measure our impact on nature and will seek to accredit our target when the methodology is finalised.

As thinking and standardisation matures in this field, we are open to the possibility of setting new targets to ensure we meet our goal of being net positive on nature by 2030.